<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405678</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00007112</org_study_id>
    <secondary_id>8426</secondary_id>
    <nct_id>NCT00405678</nct_id>
  </id_info>
  <brief_title>Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.</brief_title>
  <official_title>The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      To determine the effects of endurance exercise training on cardiopulmonary fitness in breast
      cancer patients undergoing neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given that this is the first study to explore the potential effects of exercise training on
      exercise capacity, tumor vascularity and response in women undergoing neoadjuvant
      chemotherapy for operable breast cancer, prior to the initiation of the full investigation,
      we will conduct a small vanguard study to ensure we can achieve acceptable exercise adherence
      rates in the absence of dose-limiting toxicities (DLTs). Specifically, three operable breast
      cancer patients will be recruited and enrolled as described below and perform exercise
      training for a minimum of six weeks. If acceptable exercise rates are observed in the absence
      of severe DLTs during this time, we will proceed with the full investigation (recruitment of
      additional 20 patients) (see Figure 2). Using a prospective, randomized design, potential
      participants will be identified and screened for eligibility by an assigned Breast Protocol
      Nurse (TBD) via medical record review of patients scheduled for their primary neoadjuvant
      chemotherapy consultation at DCCC
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine effects of endurance exercise training on cardiopulmonary fitness via a stress test</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to fitness program</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as determined by the (Functional Assessment of Cancer Therapy-Breast) FACT-B scale.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine and define feasibility for an adequately powered Phase III study.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine effects of exercise training on tumor vascularity, systemic response and tumor response.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving chemo and exercise training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving chemo only</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Training</intervention_name>
    <description>Subjects receiving chemo with exercise training</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Chemo only</intervention_name>
    <description>Subjects receiving chemo only</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed operable primary breast cancer

          -  Age 18 or older

          -  Karnofsky performance status greater than 70

          -  No previous malignancy

          -  Absence of significant cardiac disease (left ventricular ejection fraction greater
             than or equal to 50%)

          -  No hormonal replacement therapy use within the past month

          -  Not pregnant

          -  Ability to read and understand English

          -  Signed written informed consent prior to beginning protocol specific procedures

          -  Willing to travel to DUMC to exercise three times per week

          -  Primary treating oncologist approval
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee W Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American Cancer Society (2005). Cancer: Facts and Figures. ACS, Atlanta, GA.</citation>
  </reference>
  <reference>
    <citation>Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001 Jul 28;358(9278):277-86. Review.</citation>
    <PMID>11498214</PMID>
  </reference>
  <reference>
    <citation>Cutuli B, Fourquet A, Luporsi E, Arnould L, Caron Y, Cremoux Pd, Dilhuydy JM, Fondrinier E, Fourme E, Giard-Lefevre S, Blanc-Onfroy ML, Lemanski C, Mauriac L, Sigal-Zafrani B, Tardivon A, This P, Tunon de Lara C, Kirova Y, Fabre N; Federation of French Cancer Centres (FNCLCC), et le groupe de travail SOR. [Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004]. Bull Cancer. 2005 Feb;92(2):155-68. French.</citation>
    <PMID>15749645</PMID>
  </reference>
  <reference>
    <citation>Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001 Sep 15;19(18):3817-27. Review.</citation>
    <PMID>11559719</PMID>
  </reference>
  <reference>
    <citation>Rauschecker H, Clarke M, Gatzemeier W, Recht A. Systemic therapy for treating locoregional recurrence in women with breast cancer. Cochrane Database Syst Rev. 2001;(4):CD002195. Review.</citation>
    <PMID>11687148</PMID>
  </reference>
  <reference>
    <citation>Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003;(2):CD002747. Review.</citation>
    <PMID>12804433</PMID>
  </reference>
  <reference>
    <citation>Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002 Aug;110(4):475-82.</citation>
    <PMID>12189241</PMID>
  </reference>
  <reference>
    <citation>Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 2003 Apr;3(4):377-86.</citation>
    <PMID>12726863</PMID>
  </reference>
  <reference>
    <citation>Tannock IF. Tumor physiology and drug resistance. Cancer Metastasis Rev. 2001;20(1-2):123-32. Review.</citation>
    <PMID>11831640</PMID>
  </reference>
  <reference>
    <citation>Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002 Mar;8(3):878-84.</citation>
    <PMID>11895922</PMID>
  </reference>
  <reference>
    <citation>Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release. 2002 Jan 17;78(1-3):81-95.</citation>
    <PMID>11772451</PMID>
  </reference>
  <reference>
    <citation>Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. 2002 Mar 21;416(6878):279-80.</citation>
    <PMID>11907566</PMID>
  </reference>
  <reference>
    <citation>Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001 Sep;7(9):987-9. Review.</citation>
    <PMID>11533692</PMID>
  </reference>
  <reference>
    <citation>Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005 Jan 7;307(5706):58-62. Review.</citation>
    <PMID>15637262</PMID>
  </reference>
  <reference>
    <citation>Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature. 2004 Feb 19;427(6976):695.</citation>
    <PMID>14973470</PMID>
  </reference>
  <reference>
    <citation>Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004 Jun 1;64(11):3731-6.</citation>
    <PMID>15172975</PMID>
  </reference>
  <reference>
    <citation>Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004 Dec;6(6):553-63.</citation>
    <PMID>15607960</PMID>
  </reference>
  <reference>
    <citation>Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res. 2004;6(3):R191-8. Epub 2004 Mar 9.</citation>
    <PMID>15084243</PMID>
  </reference>
  <reference>
    <citation>van Diest PJ, Vleugel MM, van der Groep P, van der Wall E. VEGF-D and HIF-1alpha in breast cancer. J Clin Pathol. 2005 Mar;58(3):335; author reply 336.</citation>
    <PMID>15735177</PMID>
  </reference>
  <reference>
    <citation>van Diest, P.J., Vleugel, M.M., van der Wall, E., Currie, M.J., Hanrahan, V., Gunningham, S.P., Morrin, H.R., Frampton, C., Han, C., Robinson, B.A., and Fox, S.B. (2005). Expression of HIF-1{alpha} in human tumours. J Clin Pathol 58, 335-336.</citation>
  </reference>
  <reference>
    <citation>Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol. 2005 Feb;58(2):172-7.</citation>
    <PMID>15677538</PMID>
  </reference>
  <reference>
    <citation>Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002 May 1;62(9):2493-7.</citation>
    <PMID>11980639</PMID>
  </reference>
  <reference>
    <citation>Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol. 2004 Apr;24(7):2875-89.</citation>
    <PMID>15024076</PMID>
  </reference>
  <reference>
    <citation>Frederiksen LJ, Siemens DR, Heaton JP, Maxwell LR, Adams MA, Graham CH. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol. 2003 Sep;170(3):1003-7.</citation>
    <PMID>12913759</PMID>
  </reference>
  <reference>
    <citation>Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002 Jan;2(1):38-47. Review.</citation>
    <PMID>11902584</PMID>
  </reference>
  <reference>
    <citation>Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G; Austrian Breast and Colorectal Cancer Study Group. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002 Jun;8(6):1831-7.</citation>
    <PMID>12060624</PMID>
  </reference>
  <reference>
    <citation>Williams KJ, Cowen RL, Stratford IJ. Hypoxia and oxidative stress. Tumour hypoxia--therapeutic considerations. Breast Cancer Res. 2001;3(5):328-31. Epub 2001 Aug 7. Review.</citation>
    <PMID>11597323</PMID>
  </reference>
  <reference>
    <citation>Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res. 2004 Apr 1;10(7):2299-306.</citation>
    <PMID>15073105</PMID>
  </reference>
  <reference>
    <citation>Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005 Jun 1;23(16):3697-705. Epub 2005 Feb 28.</citation>
    <PMID>15738537</PMID>
  </reference>
  <reference>
    <citation>Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 1;23(4):792-9.</citation>
    <PMID>15681523</PMID>
  </reference>
  <reference>
    <citation>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.</citation>
    <PMID>15175435</PMID>
  </reference>
  <reference>
    <citation>Edwards DG, Schofield RS, Lennon SL, Pierce GL, Nichols WW, Braith RW. Effect of exercise training on endothelial function in men with coronary artery disease. Am J Cardiol. 2004 Mar 1;93(5):617-20.</citation>
    <PMID>14996592</PMID>
  </reference>
  <reference>
    <citation>Fogarty JA, Muller-Delp JM, Delp MD, Mattox ML, Laughlin MH, Parker JL. Exercise training enhances vasodilation responses to vascular endothelial growth factor in porcine coronary arterioles exposed to chronic coronary occlusion. Circulation. 2004 Feb 10;109(5):664-70.</citation>
    <PMID>14769688</PMID>
  </reference>
  <reference>
    <citation>Gielen S, Hambrecht R. Effects of exercise training on vascular function and myocardial perfusion. Cardiol Clin. 2001 Aug;19(3):357-68. Review.</citation>
    <PMID>11570110</PMID>
  </reference>
  <reference>
    <citation>Green DJ, Maiorana A, O'Driscoll G, Taylor R. Effect of exercise training on endothelium-derived nitric oxide function in humans. J Physiol. 2004 Nov 15;561(Pt 1):1-25. Epub 2004 Sep 16. Review.</citation>
    <PMID>15375191</PMID>
  </reference>
  <reference>
    <citation>Hambrecht R, Adams V, Erbs S, Linke A, Kränkel N, Shu Y, Baither Y, Gielen S, Thiele H, Gummert JF, Mohr FW, Schuler G. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 2003 Jul 1;107(25):3152-8. Epub 2003 Jun 16.</citation>
    <PMID>12810615</PMID>
  </reference>
  <reference>
    <citation>Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, Schuler G. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000 Feb 17;342(7):454-60.</citation>
    <PMID>10675425</PMID>
  </reference>
  <reference>
    <citation>Kingwell BA. Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB J. 2000 Sep;14(12):1685-96. Review.</citation>
    <PMID>10973917</PMID>
  </reference>
  <reference>
    <citation>Kingwell BA. Nitric oxide as a metabolic regulator during exercise: effects of training in health and disease. Clin Exp Pharmacol Physiol. 2000 Apr;27(4):239-50. Review.</citation>
    <PMID>10779120</PMID>
  </reference>
  <reference>
    <citation>Kingwell BA, Jennings GL, Dart AM. Exercise and endothelial function. Circulation. 2000 Nov 28;102(22):E179.</citation>
    <PMID>11094053</PMID>
  </reference>
  <reference>
    <citation>Allen JD, Geaghan JP, Greenway F, Welsch MA. Time course of improved flow-mediated dilation after short-term exercise training. Med Sci Sports Exerc. 2003 May;35(5):847-53.</citation>
    <PMID>12750596</PMID>
  </reference>
  <reference>
    <citation>Allen JD, Welsch M, Aucoin N, Wood R, Lee M, LeBlanc KE. Forearm vasoreactivity in type 1diabetic subjects. Can J Appl Physiol. 2001 Feb;26(1):34-43. English, French.</citation>
    <PMID>11173668</PMID>
  </reference>
  <reference>
    <citation>Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998 Dec 15;98(24):2709-15.</citation>
    <PMID>9851957</PMID>
  </reference>
  <reference>
    <citation>Walsh JH, Bilsborough W, Maiorana A, Best M, O'Driscoll GJ, Taylor RR, Green DJ. Exercise training improves conduit vessel function in patients with coronary artery disease. J Appl Physiol (1985). 2003 Jul;95(1):20-5.</citation>
    <PMID>12794092</PMID>
  </reference>
  <reference>
    <citation>Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.</citation>
    <PMID>14988094</PMID>
  </reference>
  <reference>
    <citation>Laufs U, Werner N, Link A, Endres M, Wassmann S, Jürgens K, Miche E, Böhm M, Nickenig G. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004 Jan 20;109(2):220-6. Epub 2003 Dec 22.</citation>
    <PMID>14691039</PMID>
  </reference>
  <reference>
    <citation>Rehman J, Li J, Parvathaneni L, Karlsson G, Panchal VR, Temm CJ, Mahenthiran J, March KL. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. J Am Coll Cardiol. 2004 Jun 16;43(12):2314-8.</citation>
    <PMID>15193699</PMID>
  </reference>
  <reference>
    <citation>Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997 Feb 14;275(5302):964-7.</citation>
    <PMID>9020076</PMID>
  </reference>
  <reference>
    <citation>Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001 Aug;108(3):391-7.</citation>
    <PMID>11489932</PMID>
  </reference>
  <reference>
    <citation>Jiang S, Walker L, Afentoulis M, Anderson DA, Jauron-Mills L, Corless CL, Fleming WH. Transplanted human bone marrow contributes to vascular endothelium. Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16891-6. Epub 2004 Nov 17.</citation>
    <PMID>15548607</PMID>
  </reference>
  <reference>
    <citation>Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3422-7.</citation>
    <PMID>10725398</PMID>
  </reference>
  <reference>
    <citation>Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest. 2001 Aug;108(3):399-405.</citation>
    <PMID>11489933</PMID>
  </reference>
  <reference>
    <citation>Murohara T, Ikeda H, Duan J, Shintani S, Sasaki Ki, Eguchi H, Onitsuka I, Matsui K, Imaizumi T. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest. 2000 Jun;105(11):1527-36.</citation>
    <PMID>10841511</PMID>
  </reference>
  <reference>
    <citation>Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999 Apr;5(4):434-8.</citation>
    <PMID>10202935</PMID>
  </reference>
  <reference>
    <citation>Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA, Abolmaali ND, Chavakis E, Reinheckel T, Zeiher AM, Dimmeler S. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med. 2005 Feb;11(2):206-13. Epub 2005 Jan 23.</citation>
    <PMID>15665831</PMID>
  </reference>
  <reference>
    <citation>Teicher BA. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics--&gt;mechanism(s) of interaction). Cancer Metastasis Rev. 1996 Jun;15(2):247-72. Review.</citation>
    <PMID>8842498</PMID>
  </reference>
  <reference>
    <citation>Jones LW, Eves ND, Courneya KS, Chiu BK, Baracos VE, Hanson J, Johnson L, Mackey JR. Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clin Cancer Res. 2005 Sep 15;11(18):6695-8.</citation>
    <PMID>16166449</PMID>
  </reference>
  <reference>
    <citation>Zielinski MR, Muenchow M, Wallig MA, Horn PL, Woods JA. Exercise delays allogeneic tumor growth and reduces intratumoral inflammation and vascularization. J Appl Physiol (1985). 2004 Jun;96(6):2249-56. Epub 2004 Mar 12.</citation>
    <PMID>15020578</PMID>
  </reference>
  <reference>
    <citation>Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003 May 1;21(9):1660-8.</citation>
    <PMID>12721239</PMID>
  </reference>
  <reference>
    <citation>Blair SN, Kampert JB, Kohl HW 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA. 1996 Jul 17;276(3):205-10.</citation>
    <PMID>8667564</PMID>
  </reference>
  <reference>
    <citation>Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002 Mar 14;346(11):793-801.</citation>
    <PMID>11893790</PMID>
  </reference>
  <reference>
    <citation>Jones LW, Courneya KS, Fairey AS, Mackey JR. Does the theory of planned behavior mediate the effects of an oncologist's recommendation to exercise in newly diagnosed breast cancer survivors? Results from a randomized controlled trial. Health Psychol. 2005 Mar;24(2):189-97.</citation>
    <PMID>15755233</PMID>
  </reference>
  <reference>
    <citation>Jones LW, Courneya KS, Fairey AS, Mackey JR. Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med. 2004 Oct;28(2):105-13.</citation>
    <PMID>15454357</PMID>
  </reference>
  <reference>
    <citation>Jones LW, Courneya KS. Exercise counseling and programming preferences of cancer survivors. Cancer Pract. 2002 Jul-Aug;10(4):208-15.</citation>
    <PMID>12100105</PMID>
  </reference>
  <reference>
    <citation>Jones LW, Courneya KS. Exercise discussions during cancer treatment consultations. Cancer Pract. 2002 Mar-Apr;10(2):66-74.</citation>
    <PMID>11903271</PMID>
  </reference>
  <reference>
    <citation>Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003 May 1;21(9):1653-9.</citation>
    <PMID>12721238</PMID>
  </reference>
  <reference>
    <citation>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.</citation>
    <PMID>10655437</PMID>
  </reference>
  <reference>
    <citation>Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002 Feb 5;105(5):546-9. Review.</citation>
    <PMID>11827916</PMID>
  </reference>
  <reference>
    <citation>Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res. 2002 Feb 22;90(3):284-8.</citation>
    <PMID>11861416</PMID>
  </reference>
  <reference>
    <citation>Allen JD, Cobb FR, Gow AJ. Regional and whole-body markers of nitric oxide production following hyperemic stimuli. Free Radic Biol Med. 2005 May 1;38(9):1164-9.</citation>
    <PMID>15808413</PMID>
  </reference>
  <reference>
    <citation>Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997 Mar;15(3):974-86.</citation>
    <PMID>9060536</PMID>
  </reference>
  <reference>
    <citation>Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997 Jul;34(3 Suppl 2):13-9.</citation>
    <PMID>9253779</PMID>
  </reference>
  <reference>
    <citation>Stables GJ, Subar AF, Patterson BH, Dodd K, Heimendinger J, Van Duyn MA, Nebeling L. Changes in vegetable and fruit consumption and awareness among US adults: results of the 1991 and 1997 5 A Day for Better Health Program surveys. J Am Diet Assoc. 2002 Jun;102(6):809-17.</citation>
    <PMID>12067046</PMID>
  </reference>
  <reference>
    <citation>Demark-Wahnefried W, Clipp EC, McBride C, Lobach DF, Lipkus I, Peterson B, Clutter Snyder D, Sloane R, Arbanas J, Kraus WE. Design of FRESH START: a randomized trial of exercise and diet among cancer survivors. Med Sci Sports Exerc. 2003 Mar;35(3):415-24.</citation>
    <PMID>12618570</PMID>
  </reference>
  <reference>
    <citation>Demark-Wahnefried W, Morey MC, Clipp EC, Pieper CF, Snyder DC, Sloane R, Cohen HJ. Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors. Control Clin Trials. 2003 Apr;24(2):206-23.</citation>
    <PMID>12689742</PMID>
  </reference>
  <reference>
    <citation>Godin G, Jobin J, Bouillon J. Assessment of leisure time exercise behavior by self-report: a concurrent validity study. Can J Public Health. 1986 Sep-Oct;77(5):359-62.</citation>
    <PMID>3791117</PMID>
  </reference>
  <reference>
    <citation>Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985 Sep;10(3):141-6.</citation>
    <PMID>4053261</PMID>
  </reference>
  <reference>
    <citation>Segal R, Evans W, Johnson D, Smith J, Colletta S, Gayton J, Woodard S, Wells G, Reid R. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol. 2001 Feb 1;19(3):657-65.</citation>
    <PMID>11157015</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise Intervention</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Neo-Adjuvant Therapy</keyword>
  <keyword>Operable Breast Cancer Stage I-II receiving neo-adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

